scispace - formally typeset
S

Sylvie Guichard

Researcher at AstraZeneca

Publications -  90
Citations -  9380

Sylvie Guichard is an academic researcher from AstraZeneca. The author has contributed to research in topics: PI3K/AKT/mTOR pathway & mTORC2. The author has an hindex of 35, co-authored 85 publications receiving 7878 citations. Previous affiliations of Sylvie Guichard include University of Edinburgh & DuPont.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy

Daniel J. Klionsky, +1287 more
- 01 Apr 2012 - 
TL;DR: These guidelines are presented for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

Christine M. Chresta, +23 more
- 01 Jan 2010 - 
TL;DR: AZD8055 is described, a novel ATP-competitive inhibitor of mTOR kinase activity, with an IC50 of 0.8 nmol/L, which results in significant growth inhibition and/or regression in xenografts, representing a broad range of human tumor types.
Journal ArticleDOI

mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling

Vanessa Rodrik-Outmezguine, +8 more
- 01 Aug 2011 - 
TL;DR: The adaptive capabilities of oncogenic signaling networks are revealed, as AKT signaling becomes reactivated through a feedback-induced AKT species phosphorylated on T308 but lacking S473, highlighting the possible need for combinatorial approaches to block feedback-regulated pathways.
Journal ArticleDOI

Kinase-Substrate Enrichment Analysis Provides Insights into the Heterogeneity of Signaling Pathway Activation in Leukemia Cells

Pedro Casado, +6 more
- 26 Mar 2013 - 
TL;DR: KSEA is demonstrated as an untargeted method for the systematic profiling of kinase pathway activities and for increasing the understanding of diseases caused by the dysregulation of signaling pathways.
Journal ArticleDOI

Controlling ligand substitution reactions of organometallic complexes: tuning cancer cell cytotoxicity.

Fuyi Wang, +13 more
- 20 Dec 2005 - 
TL;DR: The ability to tune the chemical reactivity of this class of organometallic ruthenium arene compounds should be useful in optimizing their design as anticancer agents.